Skip to main content
  • Policy
    Get Involved
    Join BIOAction
    View Advocacy Toolkit
    Patient Advocacy
    Human Health
    Cost and Value of Biopharmaceuticals
    Antimicrobial Resistance
    Vaccines & Biodefense
    Drug Development & Review
    International
    Global Markets & Trade
    Multilateral Organizations
    Intellectual Property
    All Policy
    Patient Advocacy

    Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access.

  • Member
    Membership Options
    Become a BIO Member
    Member Directory
    Have a Voice
    Membership Eligibility
    Member Toolkit
    Benefits By Sector
    member health
    Human Health
    member startups
    Startups
    member non R&D
    Non-R&D Companies
    Member Savings
    BBS-Programs-vwr
    VWR, Part of Avantor
    75% off Lab Supplies
    Save with BIO
    Save with BIO
  • News & Insights
    Latest biotech news
    Popular blogs
    Events
    Policy
    BIO Statements
    Press Releases
    Letters, Testimony & Comments
    Amicus Briefs
    BIO Reports
    Industry Analysis Reports
    Biotech Jobs
    Economic Development Best Practices
    BIO Briefly
    Issue Briefs
    BIO.News
    I am BIO Podcast
    All News & Insights

    Sign up for the BIO.News Newsletter >

  • Events
    Event Portfolio
    Business Development
    Health
    International
    Professional Development
    Members Only
    All Events
    BIO International Convention

    June 22-25, 2026 | San Diego, CA

    Learn More
    BIO Asia-Taiwan
    BIO Europe

    November 3-5, 2025
    Vienna, Austria

    BIO Investor Forum
    Partnering @JPM Week

    January 12-15, 2026
    San Francisco, CA

    BIO Patient & Health Advocacy Summit
    BIO Investment & Growth Summit

    March 2-3, 2026
    Miami, FL

    BIO Webinars

    Explore the webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s membership services.

  • About
    About Us
    Learn about our priorities
    BIO Leadership
    Meet BIO's Senior Leadership and Board of Directors
    Biotech Basics
    Read about biotechnology
    Industry Recognition
    Get to know the outstanding people and companies BIO supports
    Careers @ BIO
    Explore job openings with BIO today
    Diversity & Inclusion >

    Our tools and initiatives on workforce development, diversity and inclusion are designed to advance a more globally competitive industry.

  • Resource Hub
    Latest Resources
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Content Hub
    Biotech News (BIO.News)
    BIO.News Newsletter
    I am BIO Podcast
    BIO Advocacy Toolkit
    Resources Hub
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Webinars
    BIO Microsites
    Clinical Trials: The Power of Participation
    Covid Vaccine Facts
  • Search Results
    Previously Searched
Logo
Logo
Home
Search
  • Policy
    Human HealthPatient AdvocacyInternationalIntellectual PropertyAll Policies
  • Member
    Become a BIO MemberBenefits By Sector
    Human HealthStartupsNon-R&D Companies
    Member DirectoryHave a VoiceMembership EligibilitySavings
  • News & Insights
    Press ReleasesBio.News BlogLetters, Testimony & CommentsAmicus BriefsIndustry Analysis ReportsBiotech JobsEconomic Development Best PracticesIssue BriefsBIO.NewsVideosAll News & Insights
  • Events
    BIO International ConventionBIO Asia-TaiwanAll Events
  • About
    About UsBIO LeadershipDiversity & InclusionBiotech BasicsIndustry RecognitionCareers @ BIO
  • Resource Hub
    Biotech News (BIO.News)BIO.News NewsletterI am BIO PodcastBIO Advocacy ToolkitBIO Early-Stage Resources HubBIO Professional DevelopmentBIO WebinarsClinical Trials: The Power of ParticipationCovid Vaccine Facts
Search Results
Previously Searched
Search Results
Previously Searched
3124 results found
Expand All
Apply All
3124 results found

BIO Comments on APHIS Strategic Plan Framework
Share
Letters, Testimony & Comments  •  July 5, 2022

Good Day BIO: Anti-science drug pricing is back
Share
Good Day BIO Newsletter  •  July 5, 2022
We're back from the holiday weekend – and we're talking about drug price controls again. Here's what you need to know, plus new research that tells us how biotech can help stop mosquito-borne disease. (572 words, 2 minutes, 51 seconds)
Read More

Good Day BIO: Chiesi Group, Pfizer join White House Climate Pledge
Share
Good Day BIO Newsletter  •  July 1, 2022
Before the long weekend, we have a quick read about BIO members joining the White House’s Health Sector Climate Pledge and the FDA’s recommendation for fall booster shots. (434 words, 2 minutes, 10 seconds) We’ll be taking a quick break on Monday, July 4. We will resume publication on Tuesday, July 5. Enjoy the holiday weekend!
Read More

Good Day BIO: CRISPR's first decade – plus, HHS appropriations, monkeypox, and more
Share
Good Day BIO Newsletter  •  June 30, 2022
We’re celebrating the 10-year anniversary of the discovery of CRISPR Cas9—and what it’s done for humans, animals, and plants. While it’s almost the holiday weekend, there’s a lot happening in D.C.: House Appropriations is marking up HHS funding for fiscal year 2023, and the Biden administration is preparing for monkeypox vaccinations and fall COVID vaccinations. (601 words, 3 minutes)
Read More

Partnering with the Department of Defense to Protect the Warfighter: Investments in National Health Security, Part 1 of 3
Share
Webinars  •  June 30, 2022
Opening Remarks: Overview and Department of Defense Priorities Investing at the Speed of Need: Novel Technologies and Platforms to Accelerate Drug Development The US Government invests in biomedical research in many ways, including direct funding of some critical R&D areas for diagnostics, vaccines, and therapeutics that could strengthen biodefense preparedness. This BIO-hosted webinar details for the biotechnology corporate and academic community the many new and previously available sources of capital, as well as the processes for applying for funding, from the US Department of Defense. The Department of Defense (DoD) is continuously engaging in efforts to protect the warfighter from a broad array of threats. Preparing for and responding to these threats requires key partnerships with the industry to develop vaccines, therapeutics, and diagnostics that are designed specifically to meet the unique needs of the warfighter in various situations. Many of the investments made through these partnerships also support broader applications of key biotechnologies for other unmet healthcare needs. This important webinar represents an opportunity for BIO members and the whole biotechnology community to get an update about the priorities and programs within the DoD and the ways companies can work with the Agency on their priorities.
Read More
772148322.png

Partnering with the Department of Defense to Protect the Warfighter: Investments in National Health Security, Part 2 of 3
Share
Webinars  •  June 30, 2022
Repurposing and Redirecting: An Alternate Approach to Accelerating Medical Countermeasures The US Government invests in biomedical research in many ways, including direct funding of some critical R&D areas for diagnostics, vaccines, and therapeutics that could strengthen biodefense preparedness. This BIO-hosted webinar details for the biotechnology corporate and academic community the many new and previously available sources of capital, as well as the processes for applying for funding, from the US Department of Defense. The Department of Defense (DoD) is continuously engaging in efforts to protect the warfighter from a broad array of threats. Preparing for and responding to these threats requires key partnerships with the industry to develop vaccines, therapeutics, and diagnostics that are designed specifically to meet the unique needs of the warfighter in various situations. Many of the investments made through these partnerships also support broader applications of key biotechnologies for other unmet healthcare needs. This important webinar represents an opportunity for BIO members and the whole biotechnology community to get an update about the priorities and programs within the DoD and the ways companies can work with the Agency on their priorities.
Read More
772148322.png

Partnering with the Department of Defense to Protect the Warfighter: Investments in National Health Security, Part 3 of 3
Share
Webinars  •  June 30, 2022
How to Work with the Department of Defense The US Government invests in biomedical research in many ways, including direct funding of some critical R&D areas for diagnostics, vaccines, and therapeutics that could strengthen biodefense preparedness. This BIO-hosted webinar details for the biotechnology corporate and academic community the many new and previously available sources of capital, as well as the processes for applying for funding, from the US Department of Defense. The Department of Defense (DoD) is continuously engaging in efforts to protect the warfighter from a broad array of threats. Preparing for and responding to these threats requires key partnerships with the industry to develop vaccines, therapeutics, and diagnostics that are designed specifically to meet the unique needs of the warfighter in various situations. Many of the investments made through these partnerships also support broader applications of key biotechnologies for other unmet healthcare needs. This important webinar represents an opportunity for BIO members and the whole biotechnology community to get an update about the priorities and programs within the DoD and the ways companies can work with the Agency on their priorities.
Read More
772148322.png

Good Day BIO: FDA panel calls for Omicron boosters
Share
Good Day BIO Newsletter  •  June 29, 2022
We have a readout from FDA’s meeting on boosters targeting COVID-19 variants and USDA’s new program to invest in biomanufacturing—plus, we’re celebrating Pride Month. (591 words, 2 minutes, 57 seconds)
Read More

Good Day BIO: Mexico’s GM corn ban a lose-lose scenario, study says
Share
Good Day BIO Newsletter  •  June 28, 2022
A new report explains why Mexico’s ban on GM corn is a lose-lose for Mexico and the U.S., and some want to use the Bayh-Dole Act to achieve “backdoor” drug price controls, which would amount to a “frontal assault” on R&D. (701 words, 3 minutes, 30 seconds)
Read More

Good Day BIO: FDA's clinical trial guidance and a long-awaited USDA nominee
Share
Good Day BIO Newsletter  •  June 27, 2022
D.C.’s in recess, but there’s a lot happening. We have a look at BIO’s recent comments on FDA’s clinical trial diversity guidance, a long-awaited USDA nominee, and why Accelerated Approval is under political attack. (772 words, 3 minutes, 51 seconds)
Read More

Pagination

  • First First page
  • Prev Previous page
  • …
  • 136
  • 137
  • 138
  • …
  • Next Next page
  • Last Last page
Biotechnology Innovation Organization
Explore BIO
Policy
Events
About
Industry Insights
Join Now
BIO PAC
For Members
Member Directory
BIO Policy Committees
Cost-Savings Program
BIO Events
BIO International Convention
BIO Partnering at JPM Week
BIO CEO & Investor Conference
BIO Investor Forum
BIO Patient Health & Advocacy Summit
BIO Intellectual Property Counsels Committee Conference
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2025 All Rights Reserved
Privacy Policy
Terms of Use
Contact BIO